Monash Launches Trial on Psychedelic Therapy for PCS
The Mirage, June 15, 2026
Monash University researchers have launched Australia’s first randomised, double-blind clinical trial investigating psilocybin-assisted therapy for persistent post-concussion symptoms — a condition affecting up to 50% of people who sustain a concussion. The $1.5 million MRFF-funded trial adds to the growing body of evidence supporting the potential of psychedelic-assisted therapies in treating conditions with few existing treatment options.
Has AI Already Killed How-To Nonfiction? Sales Trends, My Personal Data, and What It Might Mean for the Future
Tim Ferriss, June 12, 2026
In a striking piece of public transparency, bestselling author Tim Ferriss has revealed that AI is decimating sales of prescriptive nonfiction — and argues that the market for information is rapidly being replaced by chatbots. But his conclusion is a powerful one: what cannot be replaced is transformation. The human journey. The designed path. The held space. It’s a distinction that sits at the very heart of Mind Medicine Australia’s work — and a timely reminder of why what we do matters.
Why Psychedelics Are Gaining Support Across The Political Spectrum
Forbes, June 3, 2026
New polling from the UK reveals 68% of adults support the medical use of psilocybin-assisted therapy — a finding consistent across Labour, Conservative, Liberal Democrat, Green and Reform UK voters. The data, published in Forbes, highlights growing international momentum for psychedelic-assisted therapies, with Australia cited as a world leader following its landmark 2023 rescheduling of psilocybin.
VIDEO: Inside the legal MDMA and psilocybin magic mushroom trade
ABC, May 26, 2026
A recent news segment offered an inside look at Australia’s growing psychedelic-assisted therapy sector, where psilocybin and MDMA are being manufactured under strict pharmaceutical controls and used in supervised clinical settings to treat PTSD and treatment-resistant depression. Patients and clinicians alike are reporting life-changing outcomes, as demand continues to rise following Australia’s landmark 2023 regulatory change. Mind Medicine Australia was the charity which made the applications to the TGA which has placed Australia as the leader in psychedelic-assisted therapies for clinical use globally.
Five million Australians are on mental health medication. Rebekah is among those asking why
The Age, May 9, 2026
Nearly one in five Australians are on mental health-related prescriptions, around 5 million people, with 67% on antidepressants. Experts and former patients are questioning whether so many Australians need long-term medication for distress that could be better supported in other ways, as prescription numbers rose 37% between 2014–15 and 2023–24.
A psychedelic medicine performs well against depression
AFR, May 3, 2026
On February 17, Compass Pathways, a British biotech, announced strong results in two late-stage trials showing that a synthetic form of psilocybin – the active compound in magic mushrooms – can rapidly relieve symptoms in patients with treatment-resistant depression. If America’s Food and Drug Administration approves the drug, which could happen early next year, it would be the first psychedelic drug in the US to become a fully licensed medicine.
Magic mushrooms could help people quit smoking
BBC, April 30, 2026
Psychedelics like psilocybin may help people quit smoking by triggering profound shifts in perspective, with studies showing significantly higher quit rates than traditional treatments like nicotine patches. While the results are promising, researchers caution that larger and more diverse studies are needed to confirm effectiveness and fully understand how the treatment works.
FDA Awards Priority Review Vouchers to Otsuka, Compass, and Usona
Psychedelic Alpha, April 24, 2026
The FDA has issued three Commissioner’s National Priority Vouchers to leading psychedelic drug programs, fast-tracking their review timelines to as little as one to two months. The vouchers were awarded to Compass Pathways (psilocybin for treatment-resistant depression), Usona Institute (psilocybin for major depressive disorder), and Transcend Therapeutics (methylone for PTSD).
Trump signs executive order accelerating research into psychedelic drug therapies
ABC News, April 19, 2026
President Donald Trump signed an executive order Saturday that aims to accelerate research and approval of psychedelic-based therapies, especially drugs like ibogaine, for conditions such as PTSD, depression and addiction.
Auckland GP Fi Darracott-Cankovic offers all-day psychedelic trips for the terminally ill
NZ Herald, April 12, 2026
Medsafe has granted a single New Zealand doctor permission to use psilocybin in her care of the dying.
An international mega-analysis of psychedelic drug effects on brain circuit function
Nature, April 6, 2026
This study provides the most comprehensive synthesis of psychedelic brain action to date, helping resolve inconsistencies and offering a probabilistic map of how psychedelics alter large-scale brain organization.
She tried therapy and medication, but this grandmother says psilocybin is what changed her life. She’s not alone.
CNN, March 29, 2026
Martha Stem suffered a shocking loss in 2024, adding to a number of difficult life events she was determined to process during a psilocybin retreat in Oregon.
New Mexico Will Fund Psychedelic Treatment for Patients on Low Incomes
Psychedelic State(s) of America, March 18, 2026
$630,000 of New Mexico’s State Budget Designated to Equity Fund to Treat Low-Income Residents.
$740m veterans plan to fund social ‘rehabilitation’ and psychedelic treatments for PTSD
ABC, February 9, 2026
A $739 million package will support veterans to reintegrate with civilian life under expanded “rehabilitation plans” that will fund social activities, learning and community programs.
Australian researchers believe wattle may contain the ‘next gen’ of psychedelics
The Sydney Morning Herald, February 4, 2026
Dr Mitchell Low is leading a study testing 855 species of Australian wattle for its psychedelic properties, including DMT and other compounds that may be used for cutting-edge psychiatric therapies.
What Everyone Needs to Know About Antidepressants
The Forgotten Side of Medicine, January 4, 2026
The common side effects of SSRIs, the nightmare of quitting them and the safe natural alternatives for treating depression.
Czech Republic Approves Regulations For Medical Use Of Psilocybin
Forbes, December 15, 2025
Officials in the Czech Republic have approved a decree setting out the specific conditions for the use of psilocybin in treatment-resistant depression and other serious mental health disorders.
Doctors Could Legally Administer Schedule I Drugs Like MDMA And Psilocybin To Seriously Ill Patients Under New Bipartisan Bill In Congress
Marijuana Moment, December 4, 2025
Bipartisan House and Senate lawmakers have introduced a bill in Congress to allow doctors to administer Schedule I substances such as certain psychedelics to patients with life-threatening conditions.
Exploring the Link Between LSD and Anxiety
Mercola, November 15, 2025
LSD shows promise for anxiety treatment. A Phase 2b clinical trial found that 100 micrograms of MM120 (pharmaceutical LSD) reduced anxiety significantly with lasting effects.
Psychedelics might help terminal patients find peace
The Conversation, November 15, 2025
For many, the hardest part of dying isn’t physical pain but the fear, anxiety and sense of meaninglessness that often accompany it. This is where psychedelic therapy may offer support.